Skip to content

US · NVST · MEDICAL - INSTRUMENTS & SUPPLIES

Envista Holdings Corp (NVST) intrinsic value and stock valuation

$22.91as of 2026-11-21 · Mkt cap 4.66B

Data updated · price as of 2026-11-21

UndervaluedIC value is 20–50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Envista Holdings Corp DCF and intrinsic value

InvestorsCraft values NVST with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from NVST’s statements →

Envista Holdings Corp Graham Number

Graham Number: $10.79d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Brea, CA 92821-6208 envistaco.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$2.72B+7.1% 5y CAGRd
20162025
Net income
$47M+7.1% 5y CAGRd
20162025
Free cash flow
$230.4M-0.5% 5y CAGRd
20162025
Total equity
$3.11B-3.5% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$2.72B$2.51B$2.57B$2.57B$2.51B
Operating income$225.7M-$-1.04B$31.5M$319.2M$306.2M
Net income$47M-$-1.12B-$-100.2M$243.1M$340.5M
EPSd$277.8K-$-6.5M-$-600.36K$1.37M$1.92M
Operating cash flow$275.7M$336.5M$275.7M$182.7M$361.6M
Capital expenditure-$-45.3M-$-33.8M-$-58.2M-$-75.7M-$-54.7M
Free cash flow$230.4M$302.7M$217.5M$107M$306.9M
Total assets$5.68B$5.35B$6.61B$6.59B$6.57B
Total debt$1.6B$1.55B$1.65B$1.53B$1.48B
Net debt$386M$478.6M$713.6M$922.2M$410M
Total equity$3.11B$2.93B$4.17B$4.21B$4.06B
Cash and short-term investments$1.21B$1.07B$940M$606.9M$1.07B
Income statement
20252024202320222021
Revenue$2.72B$2.51B$2.57B$2.57B$2.51B
Cost of revenue$1.22B$1.12B$1.12B$1.08B$1.05B
Gross profit$1.5B$1.39B$1.45B$1.49B$1.46B
Research and development expenses$114M$99.1M$93.8M$100.1M$100.5M
Selling, general and administrative expenses$1.16B$1.14B$1.03B$1.03B$989.5M
Other expenses$0.00$1.19B$295.9M$40.7M$66.2M
Operating expenses$1.27B$2.43B$1.42B$1.17B$1.16B
Cost and expenses$2.49B$3.55B$2.54B$2.25B$2.2B
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$36.6M$46.4M$63.4M$38.4M$54.1M
Depreciation and amortization$116M$123.1M$135.6M$137.8M$123.6M
Ebitda$329.8M$279.5M$463M$497.7M$496M
Operating income$225.7M-$-1.04B$31.5M$319.2M$306.2M
Total other income/expenses, net-$-48.5M-$-46.5M-$-86.4M-$-35.3M-$-51.7M
Income before tax$177.2M-$-1.08B-$-54.9M$283.9M$254.5M
Income tax expense$130.2M$33.9M$45.3M$45.9M-$-9M
Net income$47M-$-1.12B-$-100.2M$243.1M$340.5M
Weighted average shares outstanding$168M$172.2M$166.9M$162.9M$161.2M
Weighted average diluted shares outstanding$169.2M$172.2M$166.9M$177.6M$177.6M
Balance sheet
20252024202320222021
Cash and short-term investments$1.21B$1.07B$940M$606.9M$1.07B
Net receivables$429.6M$363M$407.5M$393.5M$331.9M
Inventory$288.1M$241M$258.8M$300.8M$263.8M
Total current assets$2.03B$1.79B$1.74B$1.42B$1.84B
Property, plant and equipment, net$438.9M$419.8M$434.7M$425.4M$392.2M
Goodwill and intangible assets$2.99B$2.91B$4.25B$4.58B$4.18B
Long-term investments$0.00$26.4M$0.00$0.00-$-160.5M
Total non-current assets$3.65B$3.56B$4.86B$5.16B$4.74B
Total assets$5.68B$5.35B$6.61B$6.59B$6.57B
Accounts payable$191.6M$174.6M$179.5M$228.3M$185.8M
Short-term debt$39M$150.5M$145.6M$537M$479.8M
Deferred revenue$184.8M$146.5M$106.4M$78.9M$60.1M
Total current liabilities$852.6M$878.7M$780.8M$1.24B$1.21B
Long-term debt$1.56B$1.4B$1.51B$992.1M$1B
Deferred revenue, non-current$22.4M$20.3M$8.4M$8.6M$5.1M
Total non-current liabilities$1.72B$1.54B$1.65B$1.14B$1.31B
Capital lease obligations$149.4M$153.4M$140.2M$148.4M$144.1M
Total liabilities$2.57B$2.42B$2.43B$2.38B$2.52B
Common stock$1.8M$1.7M$1.7M$1.6M$1.6M
Retained earnings-$-440.4M-$-487.4M$631.2M$731.4M$466.9M
Accumulated other comprehensive income (loss)-$-113.2M-$-371.1M-$-217.2M-$-225.1M-$-143.5M
Total equity$3.11B$2.93B$4.17B$4.21B$4.06B
Total investments$0.00$26.4M$0.00$0.00-$-160.5M
Total debt$1.6B$1.55B$1.65B$1.53B$1.48B
Net debt$386M$478.6M$713.6M$922.2M$410M
Cash flow statement
20252024202320222021
Net income$47M-$-1.12B-$-100.2M$243.1M$340.5M
Depreciation and amortization$150.7M$154.5M$162.6M$162.1M$151.9M
Stock-based compensation$37.6M$35.3M$30.7M$30.5M$28.2M
Change in working capital$8.9M$97.4M-$-108.4M-$-271.7M-$-203.2M
Accounts receivable-$-48.5M$10M-$-17M-$-71M-$-43.2M
Inventory-$-29.1M$3.6M$35.1M-$-39.9M-$-66M
Accounts payable$7.5M-$-1.2M-$-46.3M$44.5M-$-20.3M
Net cash provided by operating activities$275.7M$336.5M$275.7M$182.7M$361.6M
Investments in property, plant and equipment-$-45.3M-$-33.8M-$-58.2M-$-75.7M-$-54.7M
Acquisitions, net$0.00$0.00$0.00-$-622.3M$310.4M
Net cash used for investing activities-$-51.1M-$-54.6M-$-62.4M-$-657.3M$262.7M
Common stock issued$2.8M$2.4M$11.3M$21.8M$19.5M
Common stock repurchased-$-166.6M$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-170.9M-$-103.7M$118.9M$12.5M-$-465.6M
Net change in cash$142.6M$129.1M$333.1M-$-466.7M$184.7M
Cash at end of period$1.21B$1.07B$940M$606.9M$1.07B
Operating cash flow$275.7M$336.5M$275.7M$182.7M$361.6M
Capital expenditure-$-45.3M-$-33.8M-$-58.2M-$-75.7M-$-54.7M
Free cash flow$230.4M$302.7M$217.5M$107M$306.9M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Envista Holdings Corp

        Envista Holdings Corporation is an enterprise dedicated to the development and distribution of a comprehensive range of dental solutions. These offerings are crucial for the identification, therapeutic intervention, and preventative care of diverse oral health issues, specifically addressing the teeth, gingiva (gums), and their supporting bone structures. The company's principal location is in Brea, California, and it maintains a workforce comprising 12,800 full-time personnel. The firm organizes its business activities into two main divisions: "Specialty Products & Technologies" and "Equipment & Consumables." The Specialty Products & Technologies division concentrates on the creation, fabrication, and promotion of sophisticated dental implant systems, advanced prosthetic devices, and their associated digital treatment software and technological advancements. This segment also provides orthodontic remedies, including bracket systems, clear aligners, and various items for dental laboratories. Conversely, the Equipment & Consumables division is responsible for conceptualizing, producing, and bringing to market a wide array of dental apparatus and vital supplies intended for professional dental clinics. This extensive catalog includes digital imaging instruments, specialized software, and visual or magnification systems; patient treatment units and other essential fixtures for dental practices; complete endodontic kits along with their complementary consumable items; materials and tools for restorative dentistry; rotary cutting tools (burs); impression-making compounds; adhesive agents and dental cements; and products designed for infection control.

        CEO
        Paul A. Keel
        Employees
        12K
        Beta
        0.86

        Explore

        Frequently asked questions

        What is the intrinsic value of Envista Holdings Corp (NVST)?

        Envista Holdings Corp (NVST) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is NVST undervalued?

        NVST trades at a price of $22.91 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.